SCHEMBL26482271

SCHEMBL26482271

CC1CC(c2cccc(-c3cnc4ccc(C=O)cn4c3=O)c2)(c2nncn2C)C1

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CBLB Q13191 20/20 0.57
CBL P22681 19/20 0.57
CBLC Q9ULV8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26482276 0.93 CBLB (0.57) CBLBCBLCBLC
SCHEMBL26480487 0.81 CBLB (0.58) CBLBCBLCBLC
SCHEMBL26101931 0.79 CBLB (0.58) CBLBCBLCBLC
SCHEMBL24821915 0.77 CBLB (0.57) CBLBCBLCBLC
SCHEMBL30792099 0.77 CBLB (0.57) CBLBCBLCBLC
SCHEMBL31251296 0.74 CBLB (0.76) CBLBCBLCBLC
SCHEMBL30938785 0.74 CBLB (0.53) CBLBCBLCBLC
SCHEMBL26481490 0.74 CBLB (0.53) CBLBCBLCBLC
SCHEMBL26481393 0.73 CBLB (0.54) CBLBCBLCBLC
SCHEMBL26106350 0.73 CBLB (0.54) CBLBCBLCBLC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042896-A1 POLYCYCLIC COMPOUND AS CBL-B INHIBITOR HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2025-02-06 US disclosed
CN-118139856-A Parallel-ring compounds as Cbl-b inhibitors 海南先声再明医药股份有限公司 2024-06-04 CN disclosed
WO-2023072273-A1 POLYCYCLIC COMPOUND AS CBL-B INHIBITOR 先声再明医药有限公司 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042896-A1 POLYCYCLIC COMPOUND AS CBL-B INHIBITOR CBLB, CBL, CBLC CBLB 1/4885CBL 2/4885CBLC 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.